Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Substance protects resilient staph bacteria

04.02.2005


Researchers have identified a promising new target in their fight against a dangerous bacterium that sickens people in hospitals, especially people who receive medical implants such as catheters, artificial joints and heart valves.



A substance found on the surface of Staphylococcus epidermidis has, for the first time, been shown to protect the harmful pathogen from natural human defense mechanisms that would otherwise kill the bacteria, according to scientists at the Rocky Mountain Laboratories (RML), part of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

S. epidermidis is one of several hard-to-treat infectious agents that can be transmitted to patients in hospitals via contaminated medical implants. The new report concludes that the substance--known as poly-gamma-DL-glutamic acid, or PGA--must be present for S. epidermidis to survive on medical implants. S. epidermidis infections are rarely fatal but can lead to serious conditions such as sepsis (widespread toxic infection) and endocarditis (inflammation of the lining of the heart and its valves).


Because of the ability of PGA to promote resistance to innate immune defenses, learning more about the protein could lead to new treatments for S. epidermidis and related Staphylococcal pathogens that also produce PGA, according to the RML scientists. In addition, they also are hoping that similar research under way elsewhere on Bacillus anthracis--the infectious agent of anthrax, which also produces PGA--will complement their work.

The report of the study, led by Michael Otto, Ph.D., will appear in the March edition of The Journal of Clinical Investigation and is now available online. Collaborators, all scientists at RML in Hamilton, MT, include Stanislava Kocianova, Ph.D.; Cuong Vuong, Ph.D.; Yufeng Yao, Ph.D.; Jovanka Voyich, Ph.D.; Elizabeth Fischer, M.A.; and Frank DeLeo, Ph.D.

"Nosocomial, or hospital-acquired, infections are a worrisome public health problem made worse by the increase in antibiotic resistance," says NIAID Director Anthony S. Fauci, M.D. "This research has initiated a promising new approach that could result in the development of better ways to prevent the spread of many different staph infections that can be acquired in health care settings."

The PGA discoveries came during Dr. Otto’s research of how Staphylococcal bacteria biofilms contribute to evading human immune defenses. Biofilms are protective cell-surface structures. Biofilm formation does not depend on PGA, but other research in Dr. Otto’s laboratory has indicated that PGA production is greater when a biofilm is present. Further, Dr. Otto says all 74 strains of S. epidermidis that his group tested also produced PGA, as did six other genetically related Staphylococcus pathogens. "This could be very important to vaccine development because the PGA is present in every strain of the organism," Dr. Otto says. "If a vaccine can be developed to negate the effect of the PGA, it could be highly successful against all pathogens in which PGA is a basis for disease development, such as Staph and anthrax."

The group used genetic and biochemical analyses to show that PGA is produced in S. epidermidis. They then used three S. epidermidis strains--one natural, one altered to eliminate PGA production and one altered to produce excess PGA--to show that PGA protects S. epidermidis from innate immune defense, human antibiotic compounds and salt concentrations similar to levels found on human skin. Dr. Otto’s group also used mice fitted with catheters to demonstrate that the S. epidermidis strain deficient of PGA was not able to cause infection while the other strains containing PGA did.

Ken Pekoc | EurekAlert!
Further information:
http://www.niaid.nih.gov

More articles from Life Sciences:

nachricht What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>